This study, published in the International Journal of Ophthalmology, evaluates two minimally invasive surgical combinations for treating Chronic Angle-Closure Glaucoma (CACG). The researchers found that while both "inside-the-eye" endoscopic approaches are safe and effective, adding endoscopic goniosynechialysis (E-GSL)—the physical stripping of adhesions in the eye's drainage angle—leads to significantly better long-term pressure control than laser treatment alone.
TL;DR
Adding endoscopic goniosynechialysis (E-GSL) to a combined cataract and laser procedure (Phaco/ECP) significantly improves long-term intraocular pressure control and reduces physical adhesions in patients with chronic angle-closure glaucoma. The "triple-procedure" approach achieved a 41.6% reduction in eye pressure over 12 months without the high-risk complications of traditional filtration surgeries.
What Problem Does This Paper Address?
Chronic Angle-Closure Glaucoma (CACG) is a leading cause of irreversible blindness, particularly in Asian populations. It occurs when the iris physically adheres to the drainage structures of the eye (the trabecular meshwork), creating "Peripheral Anterior Synechiae" (PAS) that block fluid outflow and spike intraocular pressure (IOP).
Traditional "gold standard" surgeries, like trabeculectomy, create an external drainage hole but are notorious for complications like hypotony (pressure too low), infections, and bleb failures. This paper investigates whether a combination of lens removal (Phaco), laser fluid reduction (ECP), and physical angle-opening (GSL)—all performed via an endoscope—can provide a safer, more effective alternative.
Methods
The researchers conducted a retrospective, comparative case series of 53 patients (64 eyes) with CACG. They compared two surgical strategies:
- ECP Group: Phacoemulsification (cataract surgery) + Endocyclophotocoagulation (using an endoscopic laser to "zap" the ciliary processes and reduce fluid production).
- E-GSL Group: Phacoemulsification + ECP + Endoscopic Goniosynechialysis (using an iris repositor under direct endoscopic visualization to physically peel the iris away from the drainage angle).
The use of an endoscope is the key technical differentiator here, allowing the surgeon to see and treat the drainage angle directly from the inside, bypassing issues like corneal cloudiness that hinder traditional methods.
Datasets
As a clinical research paper, the "dataset" consists of the patient cohort treated at the Chinese PLA General Hospital between 2018 and 2019:
- ECP Group: 32 eyes from 27 patients (mean age 67.5).
- E-GSL Group: 32 eyes from 26 patients (mean age 69.9). Patients were followed for 12 months, with data points collected for IOP, visual acuity (VA), medication count, and the extent of PAS (measured in degrees).
Key Insights and Ideas
- The "Triple Threat" Approach: The E-GSL group addresses the three pillars of glaucoma management: increasing space (Phaco), decreasing fluid production (ECP), and restoring the natural drainage pathway (GSL).
- Endoscopic Precision: Traditional GSL is often done "blindly" or through a goniolens. The endoscope provides high-definition, direct visualization, ensuring the surgeon actually opens the trabecular meshwork rather than just pushing on the iris.
- Inflammation Trade-off: The E-GSL group experienced more initial inflammation and a slower initial drop in IOP compared to the ECP group. However, the E-GSL group eventually achieved much lower stable pressures.
- Safety Profile: Neither group experienced the "scary" complications of traditional glaucoma surgery (macular edema, consistent uveitis, or hypotony), suggesting these endoscopic procedures are viable for patients with mild-to-moderate disease.
Key Results
- IOP Reduction: At 12 months, the E-GSL group saw a 41.6% reduction in mean IOP, compared to a 26.2% reduction in the ECP-only group.
- Angle Opening: The E-GSL group was far more effective at reducing adhesions. Post-operative PAS was only 47.81° in the E-GSL group versus 195.94° in the ECP group.
- Medication Burden: Both groups significantly reduced their reliance on eye drops. The E-GSL group dropped from 2.56 medications to 0.66; the ECP group dropped from 2.22 to 0.94.
- Visual Acuity: VA improved significantly in the ECP group. In the E-GSL group, VA remained stable (likely due to the severity of the underlying glaucoma and early post-op inflammation).
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective Design: The study looks backward at existing records, which can introduce selection bias.
- Sample Size: 64 eyes is a relatively small cohort.
- Follow-up Duration: 12 months is sufficient for short-term outcomes, but glaucoma is a lifelong disease; multi-year data is needed.
- PAS Documentation: The progression of new adhesions (PAS) during the follow-up period was not documented in detail.
Future Work: The authors suggest that prospective, randomized controlled trials with larger populations and longer follow-up periods are essential to confirm these findings and refine the surgical technique.
Summary updated